NOS1 Gene Test (Neuronal Nitric Oxide Synthase 1)

• Identify whether you carry NOS1 variants that influence neuronal nitric oxide production, which in turn modulates vascular function, synaptic plasticity, and neuroendocrine regulation.
• Help explain patterns such as hypertension, endothelial dysfunction, or cardiometabolic risk in some individuals, since specific NOS1 SNPs have been associated with coronary heart disease, hypertension, and insulin resistance.
• Add context to mental health and cognitive traits, because NOS1 derived nitric oxide shapes learning, memory, anxiety circuits, and behavioural phenotypes, and NOS1 methylation differences have been linked to panic disorder, while NOS1 variants interact with adversity to affect depression risk.
• Inform personalised strategies around vascular protection, metabolic health, and brain performance, including training, nutrition, stress management, and, in specialist contexts, choice or dosing of therapies that interact with nitric oxide pathways.
• Clarify your baseline nitric oxide synthase architecture alongside other biomarkers, so long term optimisation plans can be built on both genetics and current biology rather than population averages.

NOS1 encodes neuronal nitric oxide synthase (nNOS), one of three nitric oxide synthase isoforms that convert L arginine and oxygen into nitric oxide and L citrulline. NOS1 is calcium and calmodulin dependent and is highly enriched in the central and peripheral nervous system, where it often localises to synaptic sites via adaptor proteins such as NOS1AP and PSD95.

In addition to neurons, NOS1 is expressed in skeletal muscle, cardiac myocytes, gastrointestinal tract, and other tissues, where it participates in smooth muscle regulation, mitochondrial function, and redox balance. The NOS1 locus resides on chromosome 12q24.22 and includes multiple splice variants and regulatory regions, including CpG rich promoter areas where DNA methylation can modulate expression.

NOS1 catalyses the production of nitric oxide, a gaseous signalling molecule that diffuses locally to activate soluble guanylate cyclase, increase cGMP, and trigger signalling cascades that influence synaptic transmission, vascular tone, and cellular metabolism. In the brain, NOS1 derived nitric oxide participates in long term potentiation and depression, neuronal development, and regulation of learning and memory.

In peripheral tissues, NOS1 modulates autonomic control of smooth muscle, including peristalsis and vascular function, and regulates mitochondrial reactive oxygen species by influencing S nitrosylation and SIRT3 dependent pathways, which can protect against apoptosis and oxidative damage in some contexts. NOS1 knockout models display hypertension, insulin resistance, dyslipidaemia, and increased oxidative stress, highlighting the enzyme's role in cardiometabolic regulation.

NOS1 also influences immune pathways. NOS1 derived nitric oxide can S nitrosylate proteins such as HDAC2, altering chromatin interactions and interferon stimulated gene expression, thereby modulating inflammation, tumour progression, and immune surveillance, including effects on tumour homing lymphocytes in melanoma models.

NOS1 sits at the intersection of neurovascular, metabolic, and psychiatric health. In the central nervous system, altered NOS1 signalling has been implicated in neurodegenerative diseases, behavioural deficits, and psychiatric disorders, including links to ADHD, depression, anxiety, and schizophrenia related phenotypes through NOS1 and NOS1AP variants and methylation patterns.

In the cardiovascular system, NOS1 contributes to fine tuning of vascular tone and cardiac repolarisation, with NOS1AP mediated interactions influencing L type calcium channels and repolarising currents. Genetic studies have identified NOS1 and NOS1AP variants associated with hypertension, coronary heart disease, sudden cardiac death risk, and metabolic syndrome, emphasising the role of nitric oxide imbalance in cardiometabolic disease.

Recent work has shown that NOS1 loss of function mutations can cause congenital hypogonadotropic hypogonadism with additional deficits in olfaction, hearing, and cognition, indicating a role in GnRH neuron development and minipuberty. Pharmacological modulation of nitric oxide in these models can rescue reproductive and behavioural phenotypes, underscoring the developmental importance of NOS1 activity.

It is easy to assume that NOS1 testing and standard cardiovascular or metabolic tests tell you the same story, but they capture different layers of your biology. Blood pressure, lipids, and glucose show how your vascular and metabolic systems are performing now; flow mediated dilation and arterial stiffness measure current endothelial function; NOS1 genotyping and methylation status reveal how your neuronal and local nitric oxide signalling systems are wired and regulated over the long term.

This distinction matters because you can carry NOS1 variants associated with higher vascular or metabolic risk and still maintain healthy blood pressure and lipids when your lifestyle and treatment are aligned, while others without risk variants can develop hypertension and insulin resistance due to other genes, diet, inactivity, or stress. NOS1 offers a mechanistic lens on nitric oxide dependent regulation that complements, rather than replaces, standard clinical markers.

The influence of NOS1 variants is strongly shaped by your lifestyle, vascular environment, stress load, and coexisting conditions rather than by the gene alone, which means you have meaningful room to change the trajectory. Several modifiable factors can either buffer or amplify any genetic tendency.

• Blood pressure and vascular load: Sodium intake, alcohol, body weight, activity levels, and sleep apnea all affect vascular tone and can amplify the impact of NOS1 related nitric oxide signalling differences on hypertension and coronary risk.
• Metabolic health and insulin sensitivity: Obesity, physical inactivity, and high sugar intake drive insulin resistance and dyslipidaemia, which interact with NOS1 derived nitric oxide signalling in skeletal muscle, liver, and vasculature. Improving insulin sensitivity often reduces the practical impact of NOS1 risk variants.
• Oxidative stress and inflammation: Smoking, chronic inflammation, and oxidative stress can quench nitric oxide and uncouple NOS enzymes, turning them into superoxide producers. Antioxidant defences, nutrient status, and inflammation control help maintain healthy NOS1 function.
• Stress, mood, and sleep: Chronic stress and sleep disruption alter autonomic balance, HPA axis activity, and central nitric oxide signalling, which can unmask NOS1 related vulnerabilities in mood, anxiety, and cardiovascular regulation. Psychological support, good sleep, and stress management can mitigate this.
• Developmental and hormonal context: For reproductive and neurodevelopmental outcomes associated with rare NOS1 loss of function mutations, timing of nitric oxide availability in early life is crucial. In more common variants, puberty, sex hormones, and aging also shape how NOS1 biology shows up clinically.

Yes, and this is the norm. Many people carry NOS1 polymorphisms linked to higher risk of hypertension, coronary heart disease, or depression without developing these conditions, especially when lifestyle and other risk factors are well managed. In complex traits such as blood pressure, metabolic syndrome, or psychiatric disorders, NOS1 variants usually explain only a small fraction of overall risk.

Similarly, changes in NOS1 methylation or expression may be present without overt disease, or may reflect adaptive responses to environmental inputs. Disease often arises when NOS1 related susceptibility combines with other genetic, environmental, and behavioural stressors.

Common NOS1 genotypes mainly differ at SNPs in coding, promoter, or intronic regions that influence enzyme expression, activity, and regulation. These variants have been associated with cardiovascular, metabolic, and psychiatric phenotypes in different cohorts.

• Reference NOS1 pattern: Genotypes with typical NOS1 expression and activity. Vascular and metabolic health are primarily driven by broader polygenic background and lifestyle, with NOS1 functioning as a standard neuronal and local NO source.
• Cardiovascular risk associated variants (for example rs3782218 and related SNPs): Some NOS1 SNPs have been associated with increased risk of coronary heart disease and hypertension in population studies, pointing to a role for altered neuronal or local NO signalling in vascular regulation. Effect sizes are modest and highly modifiable.
• Metabolic and psychiatric interaction variants: NOS1 and NOS1AP variants have been linked to metabolic syndrome in schizophrenia and to depression risk in the context of financial hardship, as well as to ADHD and other behavioural traits, suggesting combined effects on neuronal signalling and metabolic regulation.
• Rare loss of function mutations: Ultrarare NOS1 mutations can cause congenital hypogonadotropic hypogonadism with sensory and cognitive comorbidities, representing high impact variants that require specialist evaluation and often have developmental timing windows for intervention.

For DNA based NOS1 testing, preparation is straightforward because your genotype does not change with diet, training, or stress. It is most useful to include NOS1 within a broader cardiovascular, metabolic, or neuropsychiatric panel so results can be interpreted in context.

If NOS1 methylation or expression is being measured in research or specialist settings, timing relative to stressors, medications, and circadian phase may matter, and you should follow the specific instructions provided. For standard genotyping in prevention focused panels, no fasting or special timing is required.

A NOS1 test is most valuable when the result will inform how you approach cardiovascular prevention, metabolic health, and brain health as part of a whole system plan. It is less useful when ordered in isolation without considering other risk factors and biomarkers.

• Strong personal or family history of early cardiovascular disease or hypertension: NOS1, alongside NOS3, lipid, and clotting genes, can provide a richer picture of vascular risk and support more proactive blood pressure, lipid, and lifestyle management.
• Complex metabolic and psychiatric profiles: In conditions such as schizophrenia or depression where metabolic syndrome and cardiovascular risk are elevated, NOS1 and NOS1AP variants can add nuance to risk stratification and preventive strategies.
• Interest in brain performance and neuroprotection: For individuals focused on learning, memory, and long term brain health, NOS1 status can complement BDNF and other neuro genes to shape training, sleep, and vascular strategies that support synaptic plasticity.
• Rare hypogonadotropic hypogonadism or developmental syndromes: In specialist endocrinology and genetics settings, NOS1 sequencing may be part of the workup when reproductive, sensory, and cognitive phenotypes suggest involvement.